Irinotecan-eluting beads - Biocompatibles

Drug Profile

Irinotecan-eluting beads - Biocompatibles

Alternative Names: CM-BC2; DEBIRI; Irinotecan bead; Irinotecan-loaded DC Bead LUMI™; Irinotecan-loaded DC BeadM1™; Irinotecan-loaded DC Bead™; PARAGON Bead

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocompatibles International
  • Developer Biocompatibles International; BTG; Singapore General Hospital
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Liver metastases
  • Phase II Cholangiocarcinoma
  • Phase I/II Glioma

Most Recent Events

  • 29 Jul 2016 BTG International terminates a phase I clinical trials in Glioma (Recurrent, Adjuvant therapy) in United Kingdom (unspecified route) (NCT02433392)
  • 13 Aug 2015 Phase-II development for Liver metastases is ongoing in USA
  • 01 Dec 2014 Universitaire Ziekenhuizen Leuven and Biocompatibles terminate a feasibility trial for Liver metastases (first-line combination therapy, unresectable disease) in Belgium prior to initiation (NCT01631539)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top